Blood
Articles in this Issue
Siglec-15 dependent alteration of the leukemia immune microenvironment
Abstract Introduction: Relapsed and refractory hematologic malignancies remain a significant clinical challenge despite integration of newer...
Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis
Abstract Introduction Sézary syndrome (SS) is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma. Historically, Black patie...
Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.
Abstract Background. Invasive fungal infections (IFIs) represent a major cause of morbidity and mortality during intensive induction therapy...
Optimizing patient selection to decrease non-relapse mortality with reduced intensity conditioning: A validation study using the CIBMTR dataset
Abstract Background Reduced-intensity conditioning (RIC) used for allogeneic hematopoietic cell transplantation (allo-HCT) is generally asso...
Genome-wide CRISPR-Cas9 screening identified GPCR regulators RIC8A and PDCL as therapeutic targets in MLN with PDGFRB fusions
Abstract Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are rare hematologic malignancies characteri...
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium
Abstract Background: BsAb have significantly improved outcomes for patients (pts) with multiply relapsed FL. However, with the availability...
Myeloid-derived suppressor cells are expanded in the antiphospholipid antibody syndrome
Abstract Introduction: Myeloid derived suppressor cells (MDSCs) constitute a heterogeneous population of immature myeloid cells that arise i...
Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial
Abstract Background. MPN-BP occurs in 5-20% of patients (pts) with prior chronic phase (ChP) MPN, and is associated with treatment refractor...
Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database
Abstract Background: Ruxolitinib (RUX) is approved for the treatment of adults with polycythemia vera (PV) have inadequate response to or ar...
Outcomes of infusional chemotherapy regimens in multiple myeloma: A retrospective review at a single center from 2018 to 2025
Abstract Introduction Infusional chemotherapies remain vital yet under-studied in multiple myeloma (MM). They continue to serve important ro...
Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation
Abstract Introduction: Epstein-Barr virus (EBV) reactivation is a common complication following allogeneic hematopoietic stem cell transplan...
Immature platelet fraction as a pre‑test probability marker for anti‑platelet IgG positivity in thrombocytopenia
Abstract Background: The differential diagnosis of thrombocytopenia is a common clinical challenge. The immature platelet fraction (IPF), me...
Benefit VA: Assessing the benefit of venetoclax addition in veterans with CLL/SLL responding to BTK inhibitor therapy
Abstract Background and Significance: The Veterans Health Administration (VA), the largest integrated healthcare system...
AZD0120 (GC012F), a BCMA/CD19 dual-targeting fastcar T-cell therapy, demonstrates potent preclinical efficacy in multiple myeloma
Abstract Introduction: BCMA-targeted CAR T-cell therapies have shown remarkable clinical benefit for patients (pts) with multiple myeloma (M...
Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study
Abstract Background: Sutacimig is a bispecific antibody designed to bind and accumulate endogenous factor VIIa (FVIIa) and localize it to ac...
CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Abstract Introduction: Targeting Bruton tyrosine kinase (BTK) has revolutionized the treatment of chronic lymphocytic leukemia/small lymphoc...
Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study
Abstract Introduction Odro, a CD20×CD3 bispecific antibody, demonstrated compelling efficacy and generally manageable sa...
UBA1a dependency leads to synthetic lethality in vacuoles, E1-ligase, x-linked, auto-inflammatory, somatic (VEXAS) syndrome
Abstract VEXAS is a recently described, monogenic auto-inflammatory condition affecting approximately 1:4000 men over 50. It is characterize...
Tumor-induced dendritic cell dysfunction impairs T-cell proliferation and confers poor prognosis in high-risk acute lymphoblastic leukemia
Abstract Background: Dendritic cells (DCs) are key regulators of long-term anti-leukemia immunity. The functional status of DCs and mechanis...
A plasma-based test for the measurable residual disease informs the response to treatment in AML patients
Abstract Background: Allogeneic hematopoietic cell transplantation (alloHCT) remains the only potentially curative treatment for many patien...
Prognostic consequences of delayed treatment in severe aplastic anemia: A challenge in resource-constrained healthcare systems
Abstract Introduction:In aplastic anemia(AA), hematologic response is the strongest predictor of overall survival(OS). However, disparities...
Retromomelo: Real-world use of momelotinib – the french experience from the FIM group
Abstract Context: Momelotinib is a novel therapy for myelofibrosis that inhibits JAK1, JAK2, and the activin A receptor type 1 (ACVR1), a re...
Real-world survival outcomes of Japanese adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ponatinib
Abstract Introduction: Ponatinib, a potent third-generation TKI, is an effective treatment for refractory Philadelphia chromosome-positive a...
Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia
Abstract Introduction: Relapsed/refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge with limited options. While CLL-...
Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial
Abstract Introduction: Immune-mediated aplastic anaemia (AA) is bone marrow failure syndrome, where T-cell mediated destruction of hematopoi...